Stay updated on Pembrolizumab in Medullary Thyroid Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision metadata updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-11T18:04:00.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    A new Revision: v3.4.2 tag was added and the previous Revision: v3.4.1 tag was removed; no study content, eligibility criteria, or navigation changes are evident.
    Difference
    0.4%
    Check dated 2026-02-11T02:20:17.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a site-wide notice about government funding lapse and NIH Clinical Center status, and updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-03T23:13:26.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Glossary is now shown on the page, and the revision metadata has been updated to v3.4.0. New metadata entries 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' were added, while the previous 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.
    Difference
    0.2%
    Check dated 2026-01-27T23:49:16.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page shows Revision: v3.3.4 replacing Revision: v3.3.3; this is a minor version update with no impact on study content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T01:50:44.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Added Maryland as a study location under the Locations section (Bethesda, MD) and updated the revision to v3.3.3. The previous Maryland Locations entry and the HHS Vulnerability Disclosure link were removed (v3.3.2).
    Difference
    0.2%
    Check dated 2025-12-23T17:17:00.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Medullary Thyroid Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page.